Moleculin Biotech vs Pyxis Oncology
MBRX and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MBRX and PYXS compare
Pyxis Oncology is the larger company, worth 16 times as much as Moleculin Biotech ($132M against $8.2M).
Moleculin Biotech scores higher on the StockData Score (6 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MBRX | PYXS |
|---|---|---|
| Size and price | ||
| Market cap | $8.2M | $132M |
| Share price | $7.87 | $1.58 |
| Change, 1 year | −96.8% | −63.8% |
| Change, 5 years | −100.0% | −87.8% |
| Beta (5Y) | 1.17 | 1.61 |
| Employees | 150K | 56 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× (better) | 3.2× |
| Profitability | ||
| Return on equity | – | −158% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.37 | 2.96 (better) |
| Altman Z-score | −19.51 | −10.32 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.89% | 40.9% |
| Held by insiders | – | 20.4% |
| Insider net buying, 12 months | – | −$107K |
| Short interest, % of float | – | 6.8% |
Go deeper
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.